Selected Factors Related to Febrile Neutropenia of Lymphoma Patients Undergoing Chemotherapy.
Article Sidebar
Main Article Content
Abstract
Purpose: To examine the occurrence of febrile neutropenia and to study the relationship between Age, Gender, Albumin, type of lymphoma, stage of cancer, number of chemotherapy sessions, comorbidities, Self-care Behavior, Physical activity and Febrile neutropenia in lymphoma patients who received chemotherapy.
Design: Descriptive Research
Methods: The study sample consisted of 114 individuals with lymphoma who received services at the Hematology outpatient department, King Chulalongkorn Memorial Hospital. The research tools used included personal data questionnaires, self-care behavior, and physical activity questionnaires. The content validity was checked to be equal to 1.0 and the reliability was checked and Cronbach's alpha coefficients were 0.76 and 0.72, respectively. Data were analyzed using descriptive statistics. and logistic regression analysis. Data were analyzed using descriptive statistics and logistic regression analysis.
Results: The research findings revealed that 34.2% of individuals with lymphoma receiving chemotherapy experienced Febrile neutropenia (FN), with the majority occurring during the first round of chemotherapy (48.7%) and febrile neutropenia occurring only once, accounting for 84.6%. Factors associated with the occurrence of febrile neutropenia included being female, age 60 or older, low levels of blood albumin (< 3.5 g/dL), advanced stage of cancer, the number of chemotherapy cycles, and the presence of comorbidities (OR=5.43, 1.68, 4.76, 1.62, 1.83, 2.33 respectively, p<.05). On the other hand, factors associated with a decreased risk of Febrile neutropenia included physical activity (OR= 0.58, p<.05). Factors unrelated to febrile neutropenia included self-care behavior and cancer type (OR=0.62, 1.15 respectively, p>.05).
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ลิขสิทธิ์ของบทความที่ตีพิมพ์เป็นของวารสารพยาบาลศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย ทั้งฉบับตีพิมพ์เป็นรูปเล่มและเอกสารออนไลน์
References
Krell D, Jones AL. Impact of effective prevention and management of febrile neutropenia. Br J Cancer. 2009;101 Suppl 1:S23-6. doi: 10.1038/sj.bjc. 6605273. Cited in: PubMed; PMID: 19756004; PMCID: PMC2752228.
De Naurois J, Novitzky-Basso I, Gill M, Marti FM, Cullen M, Roila F. Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol. 2010;21: V252-6.
Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious Diseases society of America. Clin Infect Dis. 2011;52(4):E56-93. doi: 10.1093/cid/cir073. Cited in: PubMed; PMID: 21258094.
Siriso J, Thanasilp S, and Pudtong N. Selected Factors Related to the Quality of Death of Persons with Terminal Cancer as Perceived by Family Caregivers. J Nursing Science Chulalongkorn University. 2017;29(2):112-123.
Puchisathian J, Rojnuckarin P. High incidence of febrile neutropenia in Non-Hodgkin Lymphoma patients receiving CHOP chemotherapy despite G-CSF prophylaxis. J Hematol Transfus Med. 2017;27(1): 45-55.
Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, et al. Myeloid growth factors, version 2.2017, NCCN clinical practice guidelines in Oncology. J Natl Compr Canc Netw. 2017;15 (12):1520-41. Epub 2013 Jul 2. doi: 10. 1177/1078155213492450. Cited in: PubMed; PMID: 23824496.
Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Crit Rev Oncol Hematol. 2014;90(3):190-9. Epub 2013 Jul 2. doi: 10.1177/1078155213492450. Cited in: PubMed; PMID: 23824496.
Choi YW, Jeong SH, Ahn MS, Lee HW, Kang SY, Choi J-H, et al. Patterns of neutropenia and risk factors for febrile neutropenia of fiffuse large B-Cell Lymphoma patients treated with Rituximab-CHOP. J Korean Med Sci. 2014;29(11):1493-500.
Kim YR, Kim SJ, Park Y, Oh SY, Yun HJ, Mun YC, et al. Risk factors for neutropenic fever in non-Hodgkin’s lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis. Korean J Intern Med. 2021;36(5):1181-9. Epub 2021 Jul 16. doi: 10.3904/kjim. 2020.206. Cited in: PubMed; PMID: 34265889; PMCID: PMC8435507.
Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s Lymphoma. N Engl J Med. 2018;378(4):331-44.
Moreau M, Klastersky J, Schwarzbold A, Muanza F, Georgala A, Aoun M, et al. A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies. Annals of Oncology. 2009;20(3):513-9. Epub 2009 Jan 12. doi: 10.1093/annonc/mdn655. Cited in: PubMed; PMID: 19139177.
Lekdamrongkul P. Factors associated with febrile neutropenia in acute leukemic patients receiving chemotherapy. [Thesis]. Mahidol University; 2009. (In Thai)
Yokoyama M, Kusano Y, Nishihara A, Inoue N, Nishimura N, Mishima Y, et al. Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2). Support Care Cancer. 2020;28(2):571-9. Epub 2010 Nov 20. doi: 10.1016/j.ejca.2010.10.013. Cited in: PubMed; PMID: 21095116.
Salar A, Haioun C, Rossi FG, Duehrsen U, Pettengell R, Johnsen HE, et al. The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: Findings from clinical practice. Leuk Res. 2012;36(5):548-53. Epub 2012 Mar 3. doi: 10.1016/j.leukres. 2012.02.002. Cited in: PubMed; PMID: 22385870.
Thai Health Promotion Foundation (Thai Health Promotion Foundation), Department of Health, Misistry of Publish Health. Physical activity promotion plan (B.E 2561-2573) [Internet]; 2017 [cited 2018 Dec 20]. Available from: http://resource.thaihealth.or.th/library/hot/17077
Sirichantharawat C, Pathnapalagons R. Risk factors of febrile neutropenia in patients with Lymphoma receiving chemotherapy. Health science clinical research. 2021; 36(1):74-83.
Sütcüoğlu O, Akdoğan O, Gürler F, Kurt İnci B, Özdemir N, Özet A, Yazıcı O. The role of serum albumin/globulin ratio in combination with prognostic risk indexes of febrile neutropenia. Int J Clin Pract. 2021 Jul;75(7):e14185. Epub 2021 Apr 5. doi: 10.1111/ijcp.14185. Cited in: PubMed; PMID: 33783936.
Lavie CJ, Lee DC, Sui X, Arena R, O’Keefe JH, Church TS, Milani RV, Blair SN. Effects of running on chronic diseases and cardiovascular and all-cause mortality. Mayo Clin Proc. 2015 Nov;90(11):1541-52. Epub 2015 Sep 8. doi: 10.1016/j.mayocp. 2015.08.001. Cited in: PubMed; PMID: 26362561.